3,3’4-trimethoxy-4’-rutinosylellagic acid and its acetylated derivative: Antioxidant activity and antiproliferative effects on breast cancer cells and molecular docking study
Open Access
- 28 August 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 179, 117370
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of actionFood Science & Nutrition, 2023
- Natural antioxidants from some fruits, seeds, foods, natural products, and associated health benefits: An updateFood Science & Nutrition, 2023
- Ellagic acid as a potent anticancer drug: A comprehensive review on in vitro, in vivo, in silico, and drug delivery studiesBiotechnology and Applied Biochemistry, 2021
- Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping ReviewThe Oncologist, 2021
- Ellagic Acid and Its Role in Chronic Diseases2016
- Tobacco carcinogen induces both lung cancer and non‐alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be attenuated by lycopene supplementationInternational Journal of Cancer, 2016
- Contemporary Occupational Carcinogen Exposure and Bladder CancerJAMA Oncology, 2015
- Plant Phenolics in the Prevention and Treatment of Cancer2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009
- The global health burden of infection‐associated cancers in the year 2002International Journal of Cancer, 2006